An open-label phase I dose escalation expansion study of MGY825 in adult patients with advanced non-small cell lung cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Advanced Non-small Cell Lung Cancer
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Histologically or cytologically confirmed diagnosis of advanced (metastatic or unresectable) NFE2L2/KEAP1/CUL3 mutant non-small cell lung cancer
    2. Progression after 1 platinum-based chemotherapy regimen and PD(L)-1 antibody therapy either sequentially or concurrent with chemotherapy, where indicated, for Stage IV non-small cell lung cancer
    3. Treatment with neo-adjuvant / adjuvant platinum-based therapy that progressed within 6 months of treatment are permitted to participate

You may not be eligible for this study if the following are true:

    1. Impaired cardiac function or clinically significant cardiac disease, or risk factors at screening
    2. Presence of symptomatic CNS metastases, or CNS metastases that require local CNS-directed therapy
    3. Patients treated with the following therapy that cannot be discontinued 7 days prior to the start of the study and for the duration of the study



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.